ViiV Healthcare Launches New HIV Therapy Cabenuva
… ViiV Healthcare Launches New HIV Therapy Cabenuva …

ViiV Healthcare Unveils New HIV Therapies Cabenuva and Vocabria

GlaxoSmithKline, Pfizer and Shionogi enterprise continues to advance its HIV-focused business mission and develop breakthrough treatments

ViiV’s advanced clinical research and product development efforts pay off with the creation of the unique Cabenuva tandem therapy

  • 400MG/2ML; 600MG/2ML suspension, extended-release (intramuscular)
  • 600MG/3ML; 900MG/3ML suspension, extended-release (intramuscular)

ViiV has been tasked with a challenging mission since it was started

  • 76.5%: GlaxoSmithKline
  • 13.5% Pfizer
  • 10% Shionogi
  • Cabenuva (cabotegravir and rilpivirine)
  • Combivir (lamivudine and zidovudin)
  • Dovato (dolutegravir and lamivudine)
  • Epivir (lamivudine)
  • Epzicom (abacavir and lamivudine)
  • Juluca (dolutegravir and rilpivirine)
  • Lexiva (fosamprenavir calcium)
  • Retrovir (zidovudine)
  • Rukobia (fostemsavir)
  • Selzentry (maraviroc)
  • Tivicay/ Tivicay PD (dolutegravir)
  • Triumeq (abacavir, dolutegravir, lamivudine)
  • Trizivir (abacavir, lamivudine, zidovudine)
  • Viracept (nelfinavir mesylate)
  • Vocabria (cabotegravir)
  • Ziagen (abacavir)

Market access strategy is a pivotal priority of ViiV’s mission